1-3 of 3
Jennifer Gauvin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Probability of Being in Response (PBR): A Novel Efficacy Endpoint for Chronic Graft Versus Host Disease (GvHD) Applied to the Reach-3 Study of Ruxolitinib Versus BAT

Norbert Hollaender, Ekkehard Glimm, Jennifer Gauvin, Tommaso Stefanelli, Robert Zeiser
Journal: Blood
Blood (2022) 140 (Supplement 1): 10521–10522.
https://doi.org/10.1182/blood-2022-159432
Published: 2022
Journal Articles

The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma

Clinical Trials & Observations
Andrew Spencer, Sung-Soo Yoon, Simon J. Harrison, Shannon R. Morris, Deborah A. Smith, Richard A. Brigandi, Jennifer Gauvin, Rakesh Kumar, Joanna B. Opalinska, Christine Chen
Journal: Blood
Blood (2014) 124 (14): 2190–2195.
https://doi.org/10.1182/blood-2014-03-559963
Published: 2014
Includes: Supplemental data
Journal Articles

Novel AKT Inhibitor Afuresertib In Combination With Bortezomib and Dexamethasone Demonstrates Favorable Safety Profile and Significant Clinical Activity In Patients With Relapsed/Refractory Multiple Myeloma

Peter M Voorhees, Andrew Spencer, MD, Heather J. Sutherland, MD, PhD, FRCPC, Michael E O'Dwyer, MD, FRCPI, FRCPath, Shang-Yi Huang, MD, PhD, Keith Stewart, MBA, MB, CHB, Ajai Chari, MD, Michael Rosenzwieg, MD, Ajay K. Nooka, MD, MPH, Cara A Rosenbaum, MD, Craig C Hofmeister, MD, Deborah A Smith, PharmD, Joyce M Antal, Ademi Santiago-Walker, Jennifer Gauvin, Joanna B Opalinska, Suzanne Trudel, MD
Journal: Blood
Blood (2013) 122 (21): 283.
https://doi.org/10.1182/blood.V122.21.283.283
Published: 2013